Hypertrophic Cardiomyopathy (HCM) Therapeutics Market to Reach $2.8 Billion by 2035

Hypertrophic cardiomyopathy (HCM) therapeutics market was valued at $1.5 billion in 2025 and is projected to reach $2.8 billion by 2035, expanding at a CAGR of 6.4% from 2026 to 2035. Market growth is driven by the increasing global burden of cardiovascular diseases and the rising adoption of targeted pharmacological therapies. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 20 million casualties annually, representing the leading cause of mortality worldwide. This growing prevalence is increasing the demand for effective long-term therapies for conditions such as hypertrophic cardiomyopathy, particularly in hospital and cardiology clinic settings.

Browse the full report description of “Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Cardiac Myosin Inhibitors, Beta-Blockers, Calcium Channel Blockers, Antiarrhythmic Drugs, Anticoagulants), by Disease Type (Obstructive HCM, Non-Obstructive HCM), by End-Use Industry (Hospitals, Cardiology Clinics, Ambulatory Surgical Centers), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/hypertrophic-cardiomyopathy-hcm-therapeutics-market

The market is also benefiting from advances in disease diagnosis, including wider use of echocardiography, cardiac MRI, and genetic testing that enable earlier and more accurate identification of HCM patients. Increased awareness among physicians regarding differentiated treatment approaches for obstructive and non-obstructive forms of the disease is improving prescription rates for modern therapies. In addition, favorable regulatory support for novel cardiac myosin inhibitors and ongoing clinical development programs by companies such as Bristol Myers Squibb and Cytokinetics are strengthening the commercial outlook. Expansion of specialty cardiology centers and improved reimbursement access in developed healthcare systems are expected to further support sustained market growth over the forecast period.

Innovation Leaders Transforming the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

The key players in the hypertrophic cardiomyopathy (HCM) therapeutics market include top companies such as Johnson & Johnson, Merck & Co., Pfizer, Novartis, and Bayer AG, among others. The market is witnessing steady growth due to the increasing diagnosis rates of obstructive HCM and advancements in precision medicine. Pharmaceutical companies are focusing on expanding their cardiovascular portfolios and improving patient outcomes through innovative drug therapies. Additionally, growing awareness and improved access to specialized cardiology care are supporting market expansion globally.

• In March 2026, Bristol Myers Squibb presented new clinical and real-world data for Camzyos (mavacamten) at the American College of Cardiology (ACC.26), reinforcing its leadership in obstructive hypertrophic cardiomyopathy (oHCM) treatment. The Phase III SCOUT-HCM trial demonstrated significant efficacy and safety in adolescent patients, highlighting the drug’s potential as a first-in-class cardiac myosin inhibitor for this population.

• In December 2025, Cytokinetics announced that the US FDA approved MYQORZO (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), aimed at improving functional capacity and symptoms. The drug is a cardiac myosin inhibitor and represents a significant advancement in targeted HCM therapy. The approval was supported by positive Phase III clinical trial results demonstrating improved patient outcomes.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-

• By Drug Class
• By Disease Type
• By End User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Johnson & Johnson, Merck & Co., Pfizer, Novartis, and Bayer AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report Segment

By Drug Class

• Cardiac Myosin Inhibitors
• Beta-Blockers
• Calcium Channel Blockers
• Antiarrhythmic Drugs
• Anticoagulants

By Disease Type

• Obstructive HCM (oHCM)
• Non-Obstructive HCM (nHCM)

By End User

• Hospitals
• Cardiology Clinics
• Ambulatory Surgical Centers (ASCs)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hypertrophic-cardiomyopathy-hcm-therapeutics-market